Kornimate/medical-research-clean huggingface dataset:
the spinopelvic parameters, body mass index and waist circumference in patientd chronic non-specific low back pain

Conditions: Low Back Pain

Summary: this pilot study aims at styding the correlations between body mass index, waist circumference and the potential for positional adaptation of the pelvis to support overweight or obesity

record cards of patients presenting with non specific low back pain between january 1st 2020 and december 23rd 2022 were analysed. all included patients had undergone a full spine x-ray allowing to calculate the pelvic index (pi). weight status was described in 4 categories, in-line with the who definitions; underweight (boddy mass index (bmi)) \< 18.5 kg/m²; normal weight bmi 18.5 - 24.9 kg/m² , overweight bmi 25 - 29.9 kg/m², and obesity bmi ≥ 30 kg/m². to identify people with increased bmi-values and central (abdominal) fat distribution, we used the waist circumference (wc). the cut-off points of waist measurement that are used are 102 cm and 88 cm for men and women respectively. a high sacral slope (ss) means a greater the lumbar curvature, which results in a dynamic back. due to the correlation between ss and pi, people with high pi values generally have higher values of ss. therefore types 1 and 2 have a low-grade pi and types 3 and 4 have a high-grade pi analysis of 272 patient records, shows that the mean pi is significantly different in the group with a low wc compared with the group with a high wc. bmi and wc show a significant correlation with pi

Eligibility criteria:
inclusion criteria: * presenting with non-specific low back pain * having undergone full spine x-ray during the diagnostic proces exclusion criteria: * patients with missing data * double entry of patients

Keywords: weight, body mass index pelvic index waist circumference
conmana combined with thalidomide to treat nsclc

Conditions: NSCLC

Summary: our study the nsclc harbors egfr-mutation with conmana combined with thalidomide as first-line treatment, is expected to improve further egfr-tyrosine kinase inhibitors (tki) response rate (orr), prolong time to progression (pfs), improve patient survival.

primary objective: to evaluate the efficacy, survival and side effects of the combined therapy, and to evaluate the effectiveness and safety of thalidomide with conmana in patients who harbors egfr mutations.

Eligibility criteria:
inclusion criteria: 1. patients must have the ability to understand and the willingness to sign a written informed consent document. 2. patients be age \>18 years and \< 75 years. patients must have a life expectancy of greater than 3 months. 3. patients must be nsclc confirmed by histological or cytological. 4. eastern cooperative oncology group (ecog) score standard: 0-2. 5. patients must have normal organ and marrow function as defined below, within two week prior to study: absolute neutrophil count\>1,500/ml platelets\>100,000/ml total bilirubin: within normal institutional limits aspartate transaminase (ast)/alanine aminotransferase (alt) \ 1+ then a 24 hour urine for protein must demonstrate \<500mg of protein in 24 hours to allow participation in the study. 6. women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 7. judging by the researchers, that patients can comply with the program. exclusion criteria: 1. women that are pregnant or breastfeeding note: pregnant women are excluded from this study because the agents used in this study may be teratogenic to a fetus. because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with thalidomide, breastfeeding women are also excluded from this study. 2. during the course of the treatment, the serious active infection of intravenous injection of antibiotics is required. 3. patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to thalidomide and icotinib or other agents used in the study are excluded. 4. a person who is not effectively controlled, has symptoms of brain metastases, or suffers from a mental disorder that is not easily controlled; has a severe mental or cognitive impairment. 5. congestive heart failure, arrhythmia, myocardial infarction, unstable angina, stroke or transient ischemic attack in 6 months. 6. 5 years of suffering from other malignancies, except for the treatment of cervical carcinoma in situ or skin squamous cell carcinoma of the skin, or the basic control of skin basal cell carcinoma. 7. can not follow the test program or can not meet the follow-up of patients. 8. the researchers think it is not appropriate to participate in this trial.

Keywords: conmana thalidomide nsclc egfr mutation
feasibility and safety of neuroflo in stroke patients receiving tissue plasminogen activator

Conditions: Ischemic Stroke

Summary: to assess the safety and feasibility of using the neuroflo catheter to treat acute ischemic stroke patients following administration of intravenous tpa.


Eligibility criteria:
inclusion criteria: * ischemic stroke * nihss between 5-22 * persistent clinical deficits following administration of rt-pa exclusion criteria: * planned thrombectomy * aortic pathology * severe heart disease * other conditions the doctor will assess
effects of positive end-expiratory pressure on intracranial pressure in patients with severe traumatic brain injury

Conditions: Traumatic Brain Injury; Mechanical Ventilation Complication

Summary: the impact of peep on icp was dependent on the difference between elevated cvp levels and baseline icp levels. icp would increase once elevated cvp through peep adjustment exceeds the baseline icp.

all patients were exposed to incremental peep levels of 0, 5, 10, and 15cmh2o with 100% of fio2. the measurements were done bedside on stabilized hemodynamics and intracranial pressure. the measurement was discontinued if the following situation presented and remedies were applied accordingly: (1) cpp \ 25 mmhg (peep was restored to 0); (3) increase of pressure plateau \> 35 cmh2o (tidal volume was decreased and petco2 was maintained at 30\~35mmhg); (4) spo2 \< 90% (peep was restored to 0); and (5) suspicion of pneumothorax (peep was restored to 0 and chest radiography was performed). an equilibration period (at least 90 seconds) was entailed to ensure a normalized baseline petco2 through modulating tidal volume and respiratory rate. icp, cvp, pj, and map were measured twice or more at each level of peep for consecutively five days after admission. cpp was calculated according to the following equation: cpp=map-icp. the difference between baseline icp and cvp was categorized into the following three groups according to the previous findings: group i,ivpd ≤ 3mmhg, group ii, 3 \ 6 mmhg. relationships between peep and icp, cvp and map, cvp and pj were analyzed in each group respectively.

Eligibility criteria:
inclusion criteria: * all patients diagnosed with stbi (gcs≤8) and applied with mv were initially included. exclusion criteria: * brain death * younger than 18 or older than 80 years * pregnancy * hemodynamic instability：for example heart rate \>120 bpm or cpp \<60 mmhg * bulbous lung or pneumothorax * myocardial infarction * refusal of consent

Keywords: positive end-expiratory pressure(peep) intracranial pressure(icp) central venous pressure(cvp) intracranial central venous pressure difference(ivpd)
clinical evaluation of two monthly replacement silicone hydrogel contact lenses

Conditions: Myopia; Astigmatism

Summary: the purpose of this study is to evaluate differences in the comfort at the end of the month between air optix® lenses versus biofinity® lenses in habitual daily wear symptomatic soft contact lens wearers.


Eligibility criteria:
inclusion criteria: * must sign written informed consent document. * currently wearing weekly/biweekly or monthly sphere or toric soft contact lenses (not including air optix aqua, air optix night \& day aqua, air optix for astigmatism, biofinity sphere, biofinity toric, or proclear toric soft contact lenses) bilaterrally (in both eyes) and have worn these lenses for at least 3 months, daily wear use only (no extended wear). * symptomatic for contact lens-related ocular discomfort at the end of the lens wearing day. * current contact lens prescription within the available parameters of both study products. * able to achieve visual acuity (va) of at least 6/7.5 (20/25) in each eye with study lenses in the available parameters. * willing to wear study lenses for at least 4 hours/day and at least 5 days/week for the 1 month trial period. * willing and able to follow instructions, study procedures and maintain the appointment schedule. * other protocol-defined inclusion criteria may apply. exclusion criteria: * neophytes and current wearers of air optix aqua, air optix night \& day aqua, air optix for astigmatism, biofinity sphere, biofinity toric, or proclear toric soft contact lenses. * any systemic or ocular disease or disorder (refractive disorder allowed and dry eye is permitted), complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study. * recent (within 7 days of enrollment) or current ocular infections, active ocular inflammation, glaucoma or preauricular lymphadenopathy. * a history of ocular surgery/trauma within the last 6 months. * topical or systemic antibiotics use within 7 days of enrollment. * topical ocular or systemic corticosteroids use within 14 days of enrollment. * participation in any other ophthalmic drug or device clinical trial within 30 days of enrollment. * other protocol-defined exclusion criteria may apply.

Keywords: contact lenses myopia astigmatism
fch pet/mri parathyroid localization

Conditions: 18F-fluorocholine; Positron-Emission Tomography; Hyperparathyroidism, Primary

Summary: a prospective trial comparing the accuracy of \[f-18\]-fch pet/mri to us and 99mtc-mibi spect/ct for pre-operative parathyroid localization in patients with primary hyperparathyroidism


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * biochemically proven primary hyperparathyroidism * indication for parathyroidectomy as per institutional guidelines exclusion criteria: * contraindication for mri as per current institutional guidelines. * contraindication for gadolinium injection as per current institutional guidelines. * renal failure * inability to lie supine for at least 45 minutes. * any participant who is pregnant or breastfeeding. * participants receiving erythropoietin (i.e. for hemochromatosis; might lead to false negative results due to stimulation of bone marrow metabolism) * familial hpt syndromes * participant currently being treated with any cytotoxic chemotherapy
transcatheter arterial chemoembolization with kmg microsphere treating advance-stage hepatocellular carinomas

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of the study is to evaluate the effects of transcatheter arterial chemoembolization (tace) with kmg microsphere in treating advance-stage hepatocellular carinoma(hcc).

this is a prospective, multicentre, random, controlled clinical trial of transcatheter arterial chemoembolization (tace)with kmg microsphere treating advance-stage hepatocellular carinomas.

Eligibility criteria:
inclusion criteria: 1. hepatocellular carinomas with diagnosis of pathology or cytology or consistent with china 2001 guideline of clinical diagnosis hepatocellular carinomas 2. clinical stage（the barcelona liver clinic staging system,bclc b and c)，or can not receive surgical intervention 3. liver function:child-pugh a、b 4. pst 0-1（eastern cooperative oncology group performance score ,ecog） 5. lifespan≥6 months 6. first time to receive treatment 7. can accept the follow up 8. informed consent was gotten 9. the number of lesion ≤ 5 exclusion criteria: 1. pregnant or lactation woman 2. emotional disturbance 3. serious heart ,lung disfunction or serious diabetes mellitus 4. serious reactiveness infections;（exp:type b or c hepatitis） 5. liver function :child-pugh score c 6. thrombocyte\<6×109/l 7. diffuse hcc 8. widespread metastasis 9. serious atherosclerosis 10. acquired immunodeficiency syndrome;aids 11. thrombosis or thrombosis event in 6 months 12. renal inadequacy who need hemodialysis or peritoneal dialysis 13. with other tumors except basal cell carcinoma and carcinoma in situ of cervix 14. serious alimentary tract hemorrhage in 4 weeks

Keywords: hcc tace
study of vir-3434 in healthy volunteers and patients with chronic hepatitis b virus infection

Conditions: Chronic Hepatitis B

Summary: this is a phase 1 study in which healthy volunteers and participants with chronic hbv infection will receive vir-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (pk), and antiviral activity (only in participants with chronic hbv infection).


Eligibility criteria:
healthy volunteers: inclusion criteria: * male or female age 18 - 55 * weight 40-125 kg exclusion criteria: * any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation * history or evidence of drug or alcohol abuse * history of allergic reactions to monoclonal antibodies or antibody fragments * history of anaphylaxis chb patients: inclusion criteria: * male or female age 18 - 65 * weight 40-125 kg * chronic hbv infection for \>/= 6 months exclusion criteria: * any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation * significant fibrosis or cirrhosis * history or evidence of drug or alcohol abuse * history of chronic liver disease from any cause other than chronic hbv infection * history of hepatic decompensation * history of anaphylaxis * history of allergic reactions to monoclonal antibodies or antibody fragments * history of immune complex disease * active infection with hiv, hcv or hepatitis delta virus

Keywords: hepatitis b virus chronic hepatitis b hbv hepatitis
blood viscosity, end-stage renal disease, and mortality (beam-1)

Conditions: Renal Replacement Therapy

Summary: prospective, real-time observational study of hemodialysis patients treated with erythropoiesis-stimulating agents (esa) to currently recommended hgb targets. subjects will be evaluated dynamically for their blood viscosity status at the beginning and end of the dialysis treatment, and followed prospectively to assess outcomes. blood specimens will be collected via the subject's hemodialysis port pre- and post-hemodialysis per study assessment visit. blood will be analyzed at a designated laboratory facility for viscosity over a comprehensive range of shear rates and tested for intradialytic surges in blood viscosity. subjects will be followed for 48 weeks.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * on hemodialysis \> 3 months * on esa treatment \> 3 months * mean hgb 11 g/dl - 12 g/dl (based on at least 3 hgb results during the previous 8 weeks) * latest hgb 10.5 g/dl - 12.5 g/dl (measured within 1 week of study) exclusion criteria: * inability or unwillingness to provide informed consent * large variability in interdialytic weight gain (\>2 kg difference between low and high weight gain over last month) * more than 1 missed dialysis treatments in past month * recent bleeding * blood transfusion within 1 month * hematologic disease other than anemia * active inflammatory disease * active infection
effects of yoga training on cardiovascular reactivity to psychological stress in patients with hypertension

Conditions: Hypertension

Summary: the purpose of this study is to examine the effects of 12-week yoga training on blood pressure, heart rate, heart rate variability, arterial stiffness, and total peripheral resistance during rest and psychological stress in patients with hypertension. all eligible participants will be randomly assigned to either yoga (n=40) or usual care control (n=40) group. during the 1st lab visit, the experimenter will explain the purpose and procedures of the study. if the participants understand and agree to participate in this study, they will be asked to sign the informed consent. next, participants will fill out questionnaires, including demographic information, physical activity readiness questionnaire, perceived stress scale, anxiety inventory, exercise behavior questionnaire, and quality of life scale. participant's resting blood pressure will be measured. participants will then be instructed to relax in a supine position for 15 minutes while ecg is recording. next, participants will perform 5 minutes of stroop task and 5 minutes of mental arithmetic task (mental stressors). ecg and cardiac output will be monitored throughout the whole session. after the stress period, participants will be asked to relax until heart rate becomes stable and return to baseline. the participants will perform the sit-and-reach test. after completing all the baseline testing, the yoga group will begin the training program which is 60 minutes per session, 2 times per week for 12 weeks. the control group will be asked not to participate in any exercise program during the course of the study. participants will be filling out the same questionnaires and receive measures of blood pressure, ecg, and cardiac output at week 6 and week 12. additionally, participants will perform the stress tasks and the sit-and-reach test again at week 12.


Eligibility criteria:
inclusion criteria: * 20-65 years of age * 18.5 \<=bmi\<=29.9 * have hypertension (clinical diagnosis) * resting systolic blood pressure 120-160 mmhg, resting diastolic blood pressure lower than 110 mmhg exclusion criteria: * regular exercise behaviors or current participation in yoga programs * have cardiovascular diseases, pulmonary diseases, diabetes * have musculoskeletal problems that may affect yoga pose practice (e.g., herniated intervertebral disc, spondylolithesis, ankylosing spondylitis) * current pregnancy or breastfeeding * change of hypertension medication use within 4 weeks
optimizing weight loss outcomes through body image enhancement

Conditions: Overweight and Obesity

Summary: the study will examine if a standard group-delivered cognitive behavioral lifestyle intervention for weight loss can be improved via the incorporation of a novel body image intervention designed to address body image and improve weight loss outcomes in a sample of women with overweight/obesity.

weight loss is associated with improved morbidity and mortality in people with overweight/obesity. lifestyle-focused interventions reliably produce modest weight loss. while some comprehensive multidisciplinary weight management interventions include behavioral and psychosocial aspects of behavior change, including brief body image education, few have focused substantially on body image as a potentially salient influence on motivation and/or successful outcomes. body image is an individual's perception of their physical self. a common psychosocial correlate of obesity is body dissatisfaction, and research has shown that individuals with obesity are more often dissatisfied with their bodies than individuals without obesity. multiple studies suggest that improving body image might enhance eating self-regulation during weight management interventions and engagement in physical activity. additionally, negative body image has been associated with detrimental health outcomes, such as emotional eating and avoidance of physical activity. although body image has been addressed in the context of obesity and weight management, it is often done in a cursory manner. to date, no weight loss programs have attempted to develop a novel body image intervention that specifically targets the necessary dichotomy between body acceptance and expectable desire for body changes in a weight loss program. as such, the investigators will examine if a standard group-delivered cognitive behavioral lifestyle intervention for weight loss can be improved via the incorporation of a novel body image intervention designed to address body image and improve weight loss outcomes.

Eligibility criteria:
inclusion criteria: * age: 18 and older * sex: female * bmi of 25 kg/m2 or greater exclusion criteria: * participants unable or unwilling to provide informed consent * participants who are pregnant or planning to become pregnant over the next 4 months * participants who are breastfeeding or planning to breastfeed over the next 4 months * participants who have received a diagnosis of diabetes (type i or ii) * participants who been told not to lose weight or exercise for any reason by a healthcare provider * participants who currently have psychiatric illnesses (e.g., psychosis, schizophrenia, bipolar disorder or severe depression/anxiety) * participants who currently have persistent suicidal thoughts or have attempted suicide in the last year * participants with a history of diagnosed eating disorders such as bulimia nervosa or anorexia nervosa.
effect of visceral and parietal peritoneum suturation on postoperative vital signs

Conditions: Postoperative Pain

Summary: in this study the investigators want to asses the effect of peritonisation at c-section on postoperative vital signs which was thought to be an indirect finding secondary to increased sympathetic activity originated from pain caused by stretched peritoneum.

at c-section subject will be randomised into four groups: group1: only visceral peritoneum will be closed group 2: only parietal peritoneum will be closed group 3: both of them will be closed group 4: none of them will be closed during the postoperative period all patients will undergo vital sign screening including urine output, blood pressure measurement, pulse rate and vas score will be determined at post operative 6th hour and 24th hour.

Eligibility criteria:
inclusion criteria: * women underwent uncomplicated c-section exclusion criteria: * patient with systemic diseases * pregnant with obstetric complications * pregnant with two or more previous c-sections
niche investigated: closure of hysterotomy & evaluation of 3 suturing techniques (running, interrupted, and locked)

Conditions: Caesarean Scar Niche

Summary: this study aims to explore the impact of three different suturing techniques (running, interrupted \& locked) that used to close the uterine incision at the cesarean section on the formation of a cesarean scar niche


Eligibility criteria:
inclusion criteria: 1. women with a singleton pregnancy scheduled for elective cesarean section 2. gestational age at the time of cesarean section between 38 and 40 weeks. 3. willingness to participate in the study and provide informed consent 4. age between 18 and 35 years old. 5. bmi \<30 exclusion criteria: 1. known uterine anomalies or previous uterine surgery (e.g, myomectomy, uterine septum resection) 2. pre-existing medical conditions contraindicating cesarean delivery or affecting uterine healing (e.g., anemia, diabetes) 3. current smokers. 4. non-cephalic presentation of the fetus. 5. low-lying anterior wall placenta and placenta previa. 6. inability to provide informed consent (e.g., cognitive impairment, language barrier) 7. any condition deemed by the attending physician to pose a risk to the participant or compromise the study's integrity, for example, patients who will require excessive suturing for further hemostasis or those who require ligation of one or both uterine arteries